Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Conference News AHA 2024

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Michael O'Riordan

November 21, 2024

Presentation TCT 2024

Overview of Latest Clinical Evidence

Presenter: David Erlinge

October 30, 2024

Presentation TCT 2024

1-Year and Landmark 6-12 Month Clinical Outcomes Among Patients in Complex Lesion Subsets Treated With DynamX Bioadaptor Compared to a Contemporary Drug Eluting Stent From the INFINITY-SWEDEHEART

Presenter: David Erlinge

October 28, 2024

Presentation TCT 2024

TCT 290: Survival After PCI or CABG in Patients With NSTEMI and Left Main Disease: A Report From the SWEDEHEART Registry

Presenter: Elmir Omerovic

October 28, 2024

Presentation TCT 2024

1-Year and Landmark 6-12 Month Clinical Outcomes Among Patients in Complex Lesion Subsets Treated With DynamX Bioadaptor Compared to a Contemporary DES From the INFINITY-SWEDEHEART Randomized Clinical Trial

Presenter: David Erlinge

October 28, 2024

News Opinion Editor's Corner TCT 2024

What’s Going to Be Big at TCT 2024?

Michael O'Riordan

October 17, 2024

News Conference News ESC 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

Michael O'Riordan

September 09, 2024

Presentation ESC 2024

INFINITY-SWEDEHEART: Percutaneous coronary intervention with a Bioadaptor compared to a contemporary Drug-eluting Stent (DES) in a large broad clinical population

Presenter: David Erlinge

September 02, 2024

News Conference News ESC 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Michael O'Riordan

September 01, 2024

News Opinion Editor's Corner

What’s Going to Be Hot at ESC 2024

Shelley Wood

August 23, 2024

News Conference News ACC 2024

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Michael O'Riordan

April 07, 2024

Presentation THT 2024

Inotropes and Mortality in Patients With Cardiogenic Shock Due to Myocardial Infarction: Insights from the SWEDEHEART Registry

Presenter: Elmir Omerovic

March 05, 2024

News Daily News

No Benefit to P2Y12 Inhibitor Pretreatment in STEMI, Bern-PCI Data Confirm

Yael L. Maxwell

January 10, 2024

Advertisement

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Overview of Latest Clinical Evidence

1-Year and Landmark 6-12 Month Clinical Outcomes Among Patients in Complex Lesion Subsets Treated With DynamX Bioadaptor Compared to a Contemporary Drug Eluting Stent From the INFINITY-SWEDEHEART

TCT 290: Survival After PCI or CABG in Patients With NSTEMI and Left Main Disease: A Report From the SWEDEHEART Registry

1-Year and Landmark 6-12 Month Clinical Outcomes Among Patients in Complex Lesion Subsets Treated With DynamX Bioadaptor Compared to a Contemporary DES From the INFINITY-SWEDEHEART Randomized Clinical Trial

What’s Going to Be Big at TCT 2024?

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

INFINITY-SWEDEHEART: Percutaneous coronary intervention with a Bioadaptor compared to a contemporary Drug-eluting Stent (DES) in a large broad clinical population

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

What’s Going to Be Hot at ESC 2024

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Inotropes and Mortality in Patients With Cardiogenic Shock Due to Myocardial Infarction: Insights from the SWEDEHEART Registry

No Benefit to P2Y12 Inhibitor Pretreatment in STEMI, Bern-PCI Data Confirm

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content